Day: January 4, 2022

VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) — ElectraMeccanica Vehicles Corp. (NASDAQ: SOLO) (“ElectraMeccanica” or the “Company”), a designer and manufacturer of electric vehicles revolutionizing the urban driving experience, today announced that management will participate in the 24th Annual Needham Growth Conference taking place virtually January 10 – 14th, 2022. ElectraMeccanica management is scheduled to participate in one-on-one meetings with investors throughout the event and will host a virtual presentation as follows: 24th Annual Needham Growth Conference Date: Monday, January 10th, 2021Time: 3:30 p.m. Eastern time (12:30 p.m. Pacific time) Webcast: https://wsw.com/webcast/needham116/solo/2275042 Conference participation is by invitation only and registration is mandatory. To schedule...

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, announced today that President and CEO Oliver Peoples, Ph.D. will give a corporate presentation at the H.C. Wainwright Bioconnect Investment Conference, which is being held virtually from January 10 – 13, 2022. Yield10 management will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. Event: H.C. Wainwright Bioconnect Virtual Conference: https://hcwevents.com/bioconnect/ Time: Available as of 7:00 a.m. ET on Monday, January 10, 2022. Webcast: Click this link to view the presentation. About Yield10 Bioscience Yield10 Bioscience, Inc. is an agricultural bioscience company that is using its differentiated trait gene discovery platform, the “Trait...

BILLERICA, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today that it will provide a business update and initial expectations for 2022 before the market opens on Thursday, January 6, 2022, at approximately 7:00 a.m. Eastern Time. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Thursday, January 6, 2022, at 8:30 a.m. Eastern Time. As announced during its earnings call on November 3, 2021, Conformis will provide a planned business update. Key topics:preliminary revenue results for the fourth quarter of 2021; the initial outlook for 2022 revenue; a general business update; and a question and answer session.The webcast will be live at: https://edge.media-server.com/mmc/p/egh5izcc To attend by telephone, please use the information below for dial-in access.When...

CINCINNATI, Jan. 04, 2022 (GLOBE NEWSWIRE) — Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse” or “the Company”), an American technology company focused on providing sustainable and cost-effective drone-integrated electric vehicles to the last mile delivery sector, today announced the appointment of Robert “Bob” Ginnan as Chief Financial Officer (“CFO”), effective January 4, 2022. Ginnan succeeds Greg Ackerson who had been serving as the Company’s Interim CFO since September. Ackerson will help with Ginnan’s transition before reassuming his role as Workhorse’s Corporate Controller and Principal Accounting Officer. Ginnan comes to Workhorse with 20 plus years of senior finance and leadership experience, having most recently served as the CFO for privately held Family RV Group, the fifth largest RV dealer in the country. Over the...

‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒ BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis and defined the path for Phase 3 development of EB613, confirming that a fracture study will not be necessary and that lumbar spine BMD at 12 months can be the primary endpoint. The meeting followed completion of its Phase 2 clinical trial, which met its endpoints, including increases in lumbar spine, femoral, neck and hip bone mineral density (BMD) versus placebo after six months of treatment, and demonstrated a safety profile consistent with subcutaneous...

FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced Jim Caruso, president and CEO and Jarrod Longcor, CBO, will participate in a fireside chat at the H.C. Wainwright Bioconnect conference taking place virtually January 10-13, 2022. The fireside chat will be available on demand beginning at 7:00 am ET on January 10, 2022. To access and view the event, investors are encouraged to register by clicking on this registration link. The event also will be available on the News & Media section of the company’s website. About Cellectar Biosciences, Inc.Cellectar Biosciences is focused on the discovery and development of...

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic,...

Topline ORCA-2 Results Expected in Q2 2022 SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase 3 trial occurred in late December 2021. The ORCA-2 trial is the first Phase 3 trial in Achieve’s ORCA (Ongoing Research of Cytisinicline for Addiction) Program, designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken three times daily (TID) for either 6 or 12 weeks, compared with placebo.  Subjects in the trial received standard behavioral support...

Acquisitions to include additional rights for film, television, gaming, virtual reality and augmented reality opportunitiesArowana Media Holdings Launches Reg CF for Acquisition and Development for its Diversified Portfolio of Entertainment IP RightsArowana Media Holdings, Inc.Los Angeles, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) — Mike The Pike Productions, Inc. (OTC: MIKP) (“The Company”), ($MIKP) flagship subsidiary Arowana Media Holdings, Inc. officially announces its live offering on NetCapital.com for the company’s growing portfolio of entertainment IP rights which currently includes Dynamite Comics’ iconic Vampirella universe, Barbara O’Connor’s NYT Bestselling novel Wish, and Graeme Reynold’s visceral werewolf saga, High Moor, among others. Fans, Shareholders, and Investors interested in development stage...